IBDEI1GX ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,26330,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26330,1,3,0)
 ;;=3^Chr Kidney Disease,Stage II
 ;;^UTILITY(U,$J,358.3,26330,1,4,0)
 ;;=4^585.2
 ;;^UTILITY(U,$J,358.3,26330,2)
 ;;=^332808
 ;;^UTILITY(U,$J,358.3,26331,0)
 ;;=585.5^^154^1604^23
 ;;^UTILITY(U,$J,358.3,26331,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26331,1,3,0)
 ;;=3^Chr Kidney Disease,Stage V
 ;;^UTILITY(U,$J,358.3,26331,1,4,0)
 ;;=4^585.5
 ;;^UTILITY(U,$J,358.3,26331,2)
 ;;=^332811
 ;;^UTILITY(U,$J,358.3,26332,0)
 ;;=585.9^^154^1604^18
 ;;^UTILITY(U,$J,358.3,26332,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26332,1,3,0)
 ;;=3^Chr Kidney Disease NOS
 ;;^UTILITY(U,$J,358.3,26332,1,4,0)
 ;;=4^585.9
 ;;^UTILITY(U,$J,358.3,26332,2)
 ;;=^332812
 ;;^UTILITY(U,$J,358.3,26333,0)
 ;;=428.0^^154^1604^26
 ;;^UTILITY(U,$J,358.3,26333,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26333,1,3,0)
 ;;=3^Congestive Heart Failure,Unspec
 ;;^UTILITY(U,$J,358.3,26333,1,4,0)
 ;;=4^428.0
 ;;^UTILITY(U,$J,358.3,26333,2)
 ;;=^54758
 ;;^UTILITY(U,$J,358.3,26334,0)
 ;;=414.01^^154^1604^27
 ;;^UTILITY(U,$J,358.3,26334,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26334,1,3,0)
 ;;=3^Cor Atheroscl Native Vessel
 ;;^UTILITY(U,$J,358.3,26334,1,4,0)
 ;;=4^414.01
 ;;^UTILITY(U,$J,358.3,26334,2)
 ;;=^303281
 ;;^UTILITY(U,$J,358.3,26335,0)
 ;;=585.6^^154^1604^35
 ;;^UTILITY(U,$J,358.3,26335,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26335,1,3,0)
 ;;=3^ESRD
 ;;^UTILITY(U,$J,358.3,26335,1,4,0)
 ;;=4^585.6
 ;;^UTILITY(U,$J,358.3,26335,2)
 ;;=^303986
 ;;^UTILITY(U,$J,358.3,26336,0)
 ;;=401.9^^154^1604^41
 ;;^UTILITY(U,$J,358.3,26336,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26336,1,3,0)
 ;;=3^Hypertension
 ;;^UTILITY(U,$J,358.3,26336,1,4,0)
 ;;=4^401.9
 ;;^UTILITY(U,$J,358.3,26336,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,26337,0)
 ;;=250.00^^154^1604^28
 ;;^UTILITY(U,$J,358.3,26337,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26337,1,3,0)
 ;;=3^DM Type II w/o Complications
 ;;^UTILITY(U,$J,358.3,26337,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,26337,2)
 ;;=^331779
 ;;^UTILITY(U,$J,358.3,26338,0)
 ;;=907.2^^154^1604^45
 ;;^UTILITY(U,$J,358.3,26338,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26338,1,3,0)
 ;;=3^Late Effect SCI
 ;;^UTILITY(U,$J,358.3,26338,1,4,0)
 ;;=4^907.2
 ;;^UTILITY(U,$J,358.3,26338,2)
 ;;=^275240
 ;;^UTILITY(U,$J,358.3,26339,0)
 ;;=724.2^^154^1604^47
 ;;^UTILITY(U,$J,358.3,26339,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26339,1,3,0)
 ;;=3^Low Back Pain
 ;;^UTILITY(U,$J,358.3,26339,1,4,0)
 ;;=4^724.2
 ;;^UTILITY(U,$J,358.3,26339,2)
 ;;=^71885
 ;;^UTILITY(U,$J,358.3,26340,0)
 ;;=340.^^154^1604^53
 ;;^UTILITY(U,$J,358.3,26340,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26340,1,3,0)
 ;;=3^Multiple Sclerosis
 ;;^UTILITY(U,$J,358.3,26340,1,4,0)
 ;;=4^340.
 ;;^UTILITY(U,$J,358.3,26340,2)
 ;;=^79761
 ;;^UTILITY(U,$J,358.3,26341,0)
 ;;=278.00^^154^1604^54
 ;;^UTILITY(U,$J,358.3,26341,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26341,1,3,0)
 ;;=3^Obesity,Unspec
 ;;^UTILITY(U,$J,358.3,26341,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,26341,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,26342,0)
 ;;=301.9^^154^1604^71
 ;;^UTILITY(U,$J,358.3,26342,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26342,1,3,0)
 ;;=3^Personality Disorder NOS
 ;;^UTILITY(U,$J,358.3,26342,1,4,0)
 ;;=4^301.9
 ;;^UTILITY(U,$J,358.3,26342,2)
 ;;=^92451
 ;;^UTILITY(U,$J,358.3,26343,0)
 ;;=309.81^^154^1604^59
 ;;^UTILITY(U,$J,358.3,26343,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26343,1,3,0)
 ;;=3^PTSD
 ;;^UTILITY(U,$J,358.3,26343,1,4,0)
 ;;=4^309.81
 ;;^UTILITY(U,$J,358.3,26343,2)
 ;;=^114692
